End-to-end preclinical and clinical trial execution packages powered by proprietary chromatographic verification and translational pharmacological protocols.
Deciphering the transition from legacy empirical herbal usage to evidence-driven, molecularly calibrated, and regulatory-approved biopharmaceutical entities.
Global regulatory bodies including the US FDA, EMA, and China NMPA have tightened expectations regarding botanical drug substance characterization. The historical tolerance for vague multi-component mixtures is ending; modern clinical studies demand rigorous fingerprinting, quantified Active Pharmaceutical Ingredients (APIs), and identifiable pharmacokinetics.
The convergence of empirical traditional Chinese medicine (TCM) usage and modern Randomized Controlled Trials (RCT) allows researchers to use hospital preparation datasets as starting points. This substantially shortens the clinical development cycle by de-risking Phase I safety parameters through verified real-world observational data.
A primary failure mode of clinical trials for plant-based derivatives stems from inconsistent source material. Geographical disparities, seasonal fluctuations, and wild vs. cultivated harvesting introduce compositional shifts that compromise Phase II and Phase III reproducibility without standardized fingerprint controls.
Integrating pre-formulation extraction, molecular screening, GLP animal models, and ICH-GCP human clinical trials under one unified research entity.
Execution of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) protocols within dedicated Phase I clinical trial units. We rigorously characterize botanical active metabolites, identify maximum tolerated doses (MTD), and map preliminary systemic clearance metrics.
Exploratory multicenter studies to assess therapeutic efficacy across specific indications (e.g., metabolic disorders, chronic inflammation, neuroprotection). We establish biomarker-driven surrogate endpoints backed by robust statistical modeling and adaptive clinical trial designs.
Large-scale, double-blind, randomized, placebo-controlled clinical protocols across diverse medical institutions. Our dedicated clinical research coordinators (CRCs) and clinical research associates (CRAs) ensure data integrity and protocol compliance for new drug applications (NDAs).
Pharmacovigilance registries, safety monitoring, and expanded real-world outcome assessments. We evaluate long-term outcomes, drug-herb interactions, and supplementary therapeutic indications for approved natural medicines and regulated high-potency extracts.
Chromatographic profiling using HPTLC, HPLC-MS/MS, and GC-FID to verify target markers. We ensure chemical stability across trial batches, establishing reproducible specifications to comply with international pharmacopeia benchmarks (USP, Ph. Eur., ChP).
Before clinical exposure, our GLP-accredited safety pharmacology modules perform acute LD50 evaluations, sub-chronic rodent and canine toxicology, and in vitro Ames/micronucleus genotoxicity assays to construct reliable human equivalent dose (HED) calculations.
Realizing measurable clinical outcomes across diverse high-prevalence medical conditions through standardized natural compounds and modernized botanical formulations.
Clinical evaluation of berberine, red yeast rice, and flavonoid fractions in regulating dyslipidemia, vascular inflammation, and insulin sensitivity. Our studies incorporate continuous glucose monitoring (CGM) and flow-mediated dilation (FMD) endpoints.
Evaluating botanical compounds (such as Withania somnifera, Gastrodia elata, and standardized ginsenosides) on cognitive decline, stress resilience, and sleep architecture using polysomnography, validated psychometric scales, and serum cortisol biomarkers.
Investigating prebiotic plant polysaccharides and polyphenols on functional bowel disorders and microbiota modulation. Protocols utilize 16S rRNA metagenomic sequencing and mucosal inflammatory cytokine profiling (IL-6, TNF-alpha).
Human trials confirming the efficacy of lung-clearing TCM formulas and echinacea derivatives on acute viral clearance, systemic immune activation (CD4+/CD8+ ratios), and symptom alleviation verified across hospital pulmonary units.
Deploying AI-driven multi-target pharmacology, decentralized clinical trials (DCT), and advanced analytical omics to transform clinical botanical research.
Predictive in silico modeling to screen plant active molecules against multi-target signaling networks. This reduces target-discovery time by 60%, allowing rapid selection of potent botanical fractions before clinical entry.
Integration of remote patient monitoring, digital symptom tracking, and localized biospecimen collection. This increases patient retention, diversifies participant demographics, and yields continuous real-time safety data.
Liquid chromatography-high resolution mass spectrometry (LC-HRMS) to map individual metabolic phenotypes. We decipher variations in gut microbiotic transformation of phytochemicals, paving the way for personalized natural therapeutics.
A comprehensive operating model addressing the primary challenges in global botanical clinical trial pipelines: risk mitigation, compliance, and IP defense.
Under our contract-research framework, formulas, extraction mechanics, chromatographic methods, and clinical datasets remain 100% client-owned. Strict operational isolation guarantees complete competitive protection from concept to patent filing.
We assemble complete Module 2–5 Common Technical Documents (CTD) aligned with ICH guidelines. Sponsors receive audit-ready documentation including preclinical safety packages, batch certificates, bioanalytical validations, and clinical study reports (CSR).
Leveraging pilot facilities and GMP manufacturing lines, we formulate, label, package, and randomize Phase I–IV clinical trial materials (CTMs). This includes matching placebos designed with identical organoleptic profiles to maintain study blinding.
Practical and regulatory guidance for clinical operations leads, procurement directors, and scientific sponsors.
Select specialized development and clinical study lines to accelerate your product roadmap from preclinical stages to market registration.
